3//SEC Filing
Vivo Capital Surplus Fund VIII, L.P. 3
Accession 0001615774-18-006600
CIK 0001658247other
Filed
Jul 16, 8:00 PM ET
Accepted
Jul 17, 7:15 PM ET
Size
16.7 KB
Accession
0001615774-18-006600
Insider Transaction Report
Form 3
Vivo Capital VIII, LLC
10% Owner
Holdings
- (indirect: By Vivo Capital Fund VIII, L.P.)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (413,040 underlying) - 54,711(indirect: By LLC)
Common Stock
- (indirect: By Vivo Capital Surplus Fund VIII, L.P.)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (353,590 underlying) - (indirect: By Vivo Capital Fund VIII, L.P.)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (2,560,613 underlying) - (indirect: By Vivo Capital Surplus Fund VIII, L.P.)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (57,035 underlying)
Vivo Capital Fund VIII, L.P.
10% Owner
Holdings
- (indirect: By Vivo Capital Fund VIII, L.P.)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (413,040 underlying) - (indirect: By Vivo Capital Fund VIII, L.P.)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (2,560,613 underlying) - (indirect: By Vivo Capital Surplus Fund VIII, L.P.)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (353,590 underlying) - 54,711(indirect: By LLC)
Common Stock
- (indirect: By Vivo Capital Surplus Fund VIII, L.P.)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (57,035 underlying)
Vivo Capital Surplus Fund VIII, L.P.
10% Owner
Holdings
- (indirect: By Vivo Capital Surplus Fund VIII, L.P.)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (353,590 underlying) - (indirect: By Vivo Capital Fund VIII, L.P.)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (413,040 underlying) - (indirect: By Vivo Capital Surplus Fund VIII, L.P.)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (57,035 underlying) - (indirect: By Vivo Capital Fund VIII, L.P.)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (2,560,613 underlying) - 54,711(indirect: By LLC)
Common Stock
Vivo Capital, LLC
10% Owner
Holdings
- 54,711(indirect: By LLC)
Common Stock
- (indirect: By Vivo Capital Surplus Fund VIII, L.P.)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (353,590 underlying) - (indirect: By Vivo Capital Fund VIII, L.P.)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (2,560,613 underlying) - (indirect: By Vivo Capital Fund VIII, L.P.)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (413,040 underlying) - (indirect: By Vivo Capital Surplus Fund VIII, L.P.)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (57,035 underlying)
Footnotes (4)
- [F1]Vivo Capital LLC is the management company of Vivo Capital VIII, LLC ("Vivo LLC"). The voting members of each of Vivo Capital LLC and Vivo LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these securities. Jack B. Nielsen, M.Sc., a director of the issuer, is a Managing Director at Vivo Capital LLC. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.
- [F2]Each of the 8,424,416 and 1,163,311 shares of Series A Preferred Stock held by Vivo Capital Fund VIII, L.P. ("VCF") and Vivo Capital Surplus Fund VIII, L.P.("VCSF"), respectively, is convertible, at any time, at the holder's election, at a ratio of 3.29 to one share of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A Preferred Stock will automatically convert at a ratio of 3.29 to one share of the Issuer's common stock. The Series A Preferred Stock has no expiration date.
- [F3]Vivo LLC is the general partner of each of VCF and VCSF, the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. In addition, Albert Cha, Frank Kung, Edgar Engleman, Chen Yu and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- [F4]Each of the 1,358,903 and 187,648 shares of Series B Preferred Stock held by VCF and VCSF, respectively, is convertible, at any time, at the holder's election, at a ratio of 3.29 to one share of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock will automatically convert at a ratio of 3.29 to one share of the Issuer's common stock. The Series B Preferred Stock has no expiration date.
Documents
Issuer
Crinetics Pharmaceuticals, Inc.
CIK 0001658247
Entity typeother
Related Parties
1- filerCIK 0001628048
Filing Metadata
- Form type
- 3
- Filed
- Jul 16, 8:00 PM ET
- Accepted
- Jul 17, 7:15 PM ET
- Size
- 16.7 KB